Barrier Therapeutics is reporting positive results from an ongoing Phase IIa study of pramiconazole, an oral antifungal treatment for patients with nail fungus. Patients enrolled in the study have shown a marked clinical improvement in total signs and symptoms of onychomycosis after 16 weeks of study. Full results from the study will be presented at a future scientific meeting. Pramiconazole may also be effective for a variety of other diseases, include tinea pedis (athlete's foot), tinea corporis (ring worm), tinea cruris, tinea versicolor, vaginal candidiasis and seborrheic dermatitis.
- take a look at Barrier's release